BEVERLY, Mass. USA – March 29, 2022 – LexaGene Holdings, Inc. (OTCQB: LXXGF; TSX-V: LXG), a molecular diagnostics company, that has commercialized the MiQLab® System, a fully automated rapid pathogen testing device, today announced advancements to its sample preparation cartridge for processing complex samples.
LexaGene’s MiQLab® System is designed to process liquid samples from companion animals used in the diagnosis of infections such as urinary tract infections (UTI’s) and skin infections. The System, equipped with a MiQLab® Bacterial and AMR panel, screens samples for 10 common pathogens and 33 markers for antimicrobial resistance (AMR) testing. These AMR tests target genes that confer resistance to four classes of first-line therapeutics, namely tetracyclines, beta lactams, sulfa-TMP, and lincosamides.
Dr. Jack Regan, LexaGene’s CEO and Founder, stated, “Some sample types are easily processed for PCR testing, such as nasal swab samples, whereas other sample types, contain inhibitors that interfere with PCR. To better handle more complex samples, we have recently embedded a new chemistry into our sample preparation cartridge that greatly improves the MiQLab System’s ability to process samples that contain a significant percentage of blood, which is a powerful inhibitor of PCR. We are excited about this advancement and believe the new sample preparation cartridge broadens our testing capabilities for companion animals.”
To learn more about LexaGene and the MiQLab System or subscribe to company updates, visit lexagene.com or follow us on Twitter and LinkedIn.
On Behalf of the Board of Directors
Dr. Jack Regan
Chief Executive Officer & Chairman
For inquiries: 800.215.1824 | email@example.com or firstname.lastname@example.org
About LexaGene Holdings Inc.
LexaGene is a molecular diagnostics company that develops molecular diagnostic systems for pathogen detection and genetic testing for other molecular markers for on-site rapid testing in veterinary diagnostics, food safety and for use in open-access markets such as clinical research, agricultural testing and biodefense. End-users simply need to collect a sample, load it onto the instrument with a sample preparation cartridge, enter sample ID and press ‘go’.
The MiQLab® system delivers excellent sensitivity, specificity, and breadth of detection and can return results in approximately two hours. The unique open-access feature is designed for custom testing so that end-users can load their own real-time PCR assays onto the instrument to target any genetic target of interest.
The TSX Venture Exchange Inc. has in no way passed upon the merits of the proposed transaction and has neither approved nor disapproved the contents of this press release. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
This news release contains forward-looking information, which involves known and unknown risks, uncertainties and other factors that may cause actual events to differ materially from current expectation. Important factors — including the availability of funds, the results of financing efforts, the success of technology development efforts, the cost to procure critical parts, performance of the instrument, market acceptance of the technology, regulatory acceptance, and licensing issues — that could cause actual results to differ materially from the Company’s expectations as disclosed in the Company’s documents filed from time to time on SEDAR (see www.sedar.com). Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The company disclaims any intention or obligation, except to the extent required by law, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.